Published in J Infect Dis on June 30, 2005
Global epidemiology of HIV infection in men who have sex with men. Lancet (2012) 9.18
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Immune-driven recombination and loss of control after HIV superinfection. J Exp Med (2008) 2.34
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev (2009) 2.02
Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol (2006) 1.77
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
HIV transmission risk among HIV seroconcordant and serodiscordant couples: dyadic processes of partner selection. AIDS Behav (2008) 1.56
HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med (2013) 1.55
Association of Anaplasma marginale strain superinfection with infection prevalence within tropical regions. PLoS One (2015) 1.51
Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One (2010) 1.50
Comparison of methods to detect HIV dual infection. AIDS Res Hum Retroviruses (2010) 1.47
Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors. Arch Pediatr Adolesc Med (2009) 1.46
Innate immune sensing of HIV-1 by dendritic cells. Cell Host Microbe (2012) 1.35
Identifying HIV-1 dual infections. Retrovirology (2007) 1.25
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Frequency and implications of HIV superinfection. Lancet Infect Dis (2013) 1.19
Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J Virol (2007) 1.14
Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis (2013) 1.13
Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men. AIDS (2012) 1.10
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology (2012) 1.07
"I feel like I'm carrying a weapon." Information and motivations related to sexual risk among girls with perinatally acquired HIV. AIDS Care (2011) 1.06
Host genetics and HIV-1: the final phase? PLoS Pathog (2010) 1.06
Expansion of variant diversity associated with a high prevalence of pathogen strain superinfection under conditions of natural transmission. Infect Immun (2012) 1.00
Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007. J Acquir Immune Defic Syndr (2008) 0.96
Depression, substance use and HIV risk in a probability sample of men who have sex with men. Addict Behav (2012) 0.94
Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology (2011) 0.93
Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. Open AIDS J (2007) 0.93
A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences. BMC Health Serv Res (2007) 0.92
Knowing the consequences of unprotected sex with seroconcordant partner is associated with increased safer sex intentions among HIV-positive men in Kathmandu, Nepal. J Health Popul Nutr (2011) 0.86
Anaplasma marginale superinfection attributable to pathogen strains with distinct genomic backgrounds. Infect Immun (2014) 0.86
The role of self-efficacy and motivation to explain the effect of motivational interviewing time on changes in risky sexual behavior among people living with HIV: a mediation analysis. AIDS Behav (2013) 0.85
Preventing unintended pregnancy and HIV transmission: effects of the HIV treatment cascade on contraceptive use and choice in rural KwaZulu-Natal. J Acquir Immune Defic Syndr (2014) 0.84
Gynecologic issues in the HIV-infected woman. Infect Dis Clin North Am (2008) 0.83
Longitudinal population analysis of dual infection with recombination in two strains of HIV type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. AIDS Res Hum Retroviruses (2006) 0.82
Compensatory evolution in RNA secondary structures increases substitution rate variation among sites. Mol Biol Evol (2008) 0.81
Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok. Open Virol J (2012) 0.80
Dual Protection and Dual Methods in Women Living with HIV: The Brazilian Context. J Sex Transm Dis (2013) 0.79
Brief screening for alcohol use disorders in HIV primary care. HIV Clin (2011) 0.79
Does motivational interviewing counseling time influence HIV-positive persons' self-efficacy to practice safer sex? Patient Educ Couns (2011) 0.79
Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. J Infect Dis (2013) 0.78
Antigenic Variation in Bacterial Pathogens. Microbiol Spectr (2016) 0.78
Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus. J Virol (2007) 0.78
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis (2013) 0.78
Comment on "The origins of sexually transmitted HIV among men who have sex with men". Sci Transl Med (2010) 0.77
New approaches to vaccine adjuvants: inhibiting the inhibitor. PLoS Med (2006) 0.77
Advancing Behavioral HIV Prevention: Adapting an Evidence-Based Intervention for People Living with HIV and Alcohol Use Disorders. AIDS Res Treat (2015) 0.76
Nine challenges for deterministic epidemic models. Epidemics (2014) 0.76
Retrospective analysis of the prevalence of and factors associated with condom use among young HIV-infected women in Cameroon. SAGE Open Med (2016) 0.75
Sexual behaviour of people living with HIV attending a tertiary care government hospital in Kathmandu, Nepal: a cross sectional study. BMC Res Notes (2015) 0.75
Analysis of HIV-1 protease gene reveals frequent multiple infections followed by recombination among drug treated individuals living in São Paulo and Santos, Brazil. PLoS One (2014) 0.75
Contrasting antibody responses to intrasubtype superinfection with CRF02_AG. PLoS One (2017) 0.75
The evolutionary ecology of molecular replicators. R Soc Open Sci (2016) 0.75
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS (2016) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
Family planning knowledge and practice among people living with HIV in Nepal. PLoS One (2014) 0.75
Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles. AIDS (2017) 0.75
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54
Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol (2006) 2.48
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Whither or wither microbicides? Science (2008) 2.17
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis (2008) 2.08
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07
Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS (2003) 2.05
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis (2012) 1.99
Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83
A public health model for the molecular surveillance of HIV transmission in San Diego, California. AIDS (2009) 1.81
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76
Transmission behaviors of recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr (2006) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis (2010) 1.71
Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther (2012) 1.71
The global transmission network of HIV-1. J Infect Dis (2013) 1.68
Unprotected anal intercourse and substance use among men who have sex with men with recent HIV infection. J Acquir Immune Defic Syndr (2006) 1.66
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis (2007) 1.64
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med (2004) 1.60
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract. AIDS (2013) 1.60
Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis (2007) 1.59
SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. Chem Biol (2006) 1.58
Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS (2008) 1.55
Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol (2011) 1.55
Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr (2011) 1.54
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther (2003) 1.53
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis (2013) 1.53
HIV drug resistance acquired through superinfection. AIDS (2005) 1.52
Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS (2003) 1.52
Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol (2005) 1.52
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44
Dynamics of T cell responses in HIV infection. J Immunol (2002) 1.44
Minority variants of drug-resistant HIV. J Infect Dis (2010) 1.44
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials (2003) 1.42
Drug resistance mutations in HIV-1. Top HIV Med (2004) 1.37
The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS (2009) 1.37